Invention Grant
- Patent Title: Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
-
Application No.: US16493346Application Date: 2018-03-13
-
Publication No.: US11304929B2Publication Date: 2022-04-19
- Inventor: Harald Weinstabl , Georg Dahmann , Matthias Treu , Bernd Wellenzohn , Stephan Karl Zahn
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Wendy M. Gombert
- Priority: EP17160838 20170314
- International Application: PCT/EP2018/056170 WO 20180313
- International Announcement: WO2018/167019 WO 20180920
- Main IPC: C07D209/42
- IPC: C07D209/42 ; C07D403/04 ; C07D209/60 ; C07D471/04 ; C07D401/12 ; C07D231/14 ; C07D405/12 ; A61K31/404 ; A61K9/20 ; A61K31/4155 ; A61K31/437 ; A61K31/5377 ; A61K31/496 ; A61K45/06
Abstract:
The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Public/Granted literature
- US20220008386A1 TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS Public/Granted day:2022-01-13
Information query
